STAT+: Lilly’s breast cancer combo wins approval

STAT+ reports that Eli Lilly’s breast cancer combination has received approval. The article is a biotech newsletter roundup, and the excerpt does not provide the specific regimen, indication, or trial data behind the approval.

The roundup also notes that radiopharma players are merging after a surprise FDA rejection, Novo Nordisk plans to expand its pipeline, orexin agonists have shown an early ADHD signal, and Reed Jobs is calling for NIH funding to be doubled.